Pantoprazole Viatris (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Viatris, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome. GNH USA supplies Pantoprazole Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that decreases stomach acid production, addressing several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: facilitates mucosal repair and reduces symptom recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - NSAID‑induced gastric ulcer: aids ulcer healing and prevents recurrence. - Helicobacter pylori eradication (as part of combination therapy): enhances bacterial clearance when used with antibiotics.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Severe allergic reactions: rash, swelling, anaphylaxis. - Hypomagnesemia: low magnesium levels with prolonged use. - Vitamin B12 deficiency: potential long‑term deficiency. - Liver enzyme elevation: signs of hepatic stress. - Bone fractures: increased risk with long‑term therapy.

Before initiating therapy, consider the following safety measures. - Renal function assessment: adjust use in severe impairment. - Magnesium monitoring: check levels during prolonged treatment. - H. pylori testing: confirm infection status when indicated. - Elderly patients: use caution due to higher fracture risk. - Long‑term use evaluation: reassess necessity periodically. - Store at room temperature: keep in the original pack, protect from moisture.

Pantoprazole may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: increased pantoprazole levels. - Ketoconazole: reduced antifungal absorption. - Atazanavir: markedly decreased antiviral exposure. - HIV protease inhibitors (e.g., ritonavir): diminished efficacy. - Clopidogrel: reduced antiplatelet effect.

Moderate Interactions (Monitor Closely): - Digoxin: possible increased serum concentration. - Methotrexate: reduced renal clearance, risk of toxicity. - Warfarin: potential alteration of INR. - Phenytoin: decreased antiepileptic levels. - Diazepam: enhanced sedation risk.